Immupeutics Medicine Secures NMPA Approval for Personalized Liver Cancer Immunotherapy IPM001
Immupeutics Medicine, a pioneer in tumor immunotherapy based in Beijing, has announced that it has...
Clinical trial approval / initiation
Huadong Medicine Secures NMPA Approval for Semaglutide Biosimilar, Aims to Capture Weight Loss Market
Nanjing-based Huadong Medicine Co., Ltd (SHE: 000963) has received clinical trial approval from China’s National...
Doma Biopharmaceutical Receives Green Light for Clinical Trial of Novel ADC DM001 Targeting Solid Tumors
Doma Biopharmaceutical (Suzhou) Co., Ltd, a biotech firm with a presence in China and the...
Boehringer Ingelheim’s Survodutide Earns FDA Breakthrough Therapy Designation for MASH Treatment
German pharmaceutical company Boehringer Ingelheim has received breakthrough therapy designation (BTD) from the US Food...
Ascentage Pharma Receives Approval for Two Phase III Trials of APG-2449 in NSCLC
China-based biopharmaceutical company Ascentage Pharma (HKG: 6855) has announced that it has received approval from...
Unixell Advances in Cell Therapy with CDE IND Acceptance
Shanghai-based Unixell Biotechnology Co., Ltd. has announced that its Investigational New Drug (IND) application for...
Duality Biotherapeutics’ BDCA2 ADC DB-2304 Phase I Trial Registered on ClinicalTrials.gov
Duality Biologics, Inc., a biopharmaceutical company specializing in the development of innovative therapies, has registered...
BeiGene’s FGFR2b ADC BG-C137 Enters Phase I Clinical Trial for Advanced Solid Tumors
On October 3, 2024, BeiGene (NASDAQ: BGNE; HKG: 6160; SHA: 688235) registered a Phase I...
FRα ADC Rina-S by Genmab Enters Late-Stage Clinical Trial Following ProfoundBio Acquisition
Genmab A/S (NASDAQ: GMAB) has initiated a Phase III clinical trial for its FRα ADC...
NMPA Clears AbbVie’s ABBV-706 for Clinical Trials Targeting SCLC and Neuroendocrine Tumors
The China National Medical Products Administration (NMPA) has granted clinical trial approval to ABBV-706, a...
CStone Pharmaceuticals’ Partner HengRui Medicine Launches Phase III Trial for CTLA-4 Antibody in HCC
CStone Pharmaceuticals (HKG: 2616), an innovation-driven biopharmaceutical company focused on the development of oncology drugs,...
Sichuan Biokin’s Partner Bristol-Myers Squibb Gets FDA Nod for Bispecific ADC Study
Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a Chinese biopharmaceutical company, has announced that its...
Yabao Pharmaceutical’s SY-009 Receives NMPA Approval for Phase II Clinical Trial in Constipation
Yabao Pharmaceutical Group Co., Ltd (SHA: 600351), a Chinese pharmaceutical company, has announced that SY-009...
Jiangsu Hengrui Pharmaceuticals Gets NMPA Green Light for Clinical Trial of TSLP-Targeted Asthma Treatment
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has...
Huadong Medicine Gets NMPA Green Light for Clinical Trials of Roflumilast Cream
Huadong Medicine Co., Ltd (SHE: 000963), a Chinese pharmaceutical company, has announced that it has...
Shanghai Fosun Pharmaceutical Gets NMPA Clinical Clearance for Lymphoma Drug XS-04
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a prominent pharmaceutical company based...
Jacobio Pharma Receives NMPA Approval for Pan-KRAS Inhibitor JAB-23E73 Clinical Trial
Jacobio Pharma (HKG: 1167), a biopharmaceutical company based in China, has received approval from the...
Zelgen Biopharmaceuticals Receives NMPA Approval for ZG005 Clinical Trial in Advanced Solid Tumors
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266), a biopharmaceutical company based in China, has announced...
Jiangsu Hengrui Pharmaceuticals Gets NMPA Green Light for Generic Vizamyl Clinical Trial
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has...
Allist Pharma’s Partner Abbisko Receives NMPA Green Light for NSCLC Drug Trial
Abbisko Therapeutics Co., Ltd (HKG: 2256), a Shanghai-based biotechnology company, has announced that it has...